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Summary
Serotonin functions as an essential neuromodulator that
serves a multitude of roles, most prominently balancing
mood [1]. Serotonergic challenge has been observed to
reduce intrinsic functional connectivity in brain regions
implicated in mood regulation [2–4]. However, the full scope
of serotonergic action on functional connectivity in the hu-
man brain has not been explored. Here, we show evidence
that a single dose of a serotonin reuptake inhibitor dramati-
cally alters functional connectivity throughout the whole
brain in healthy subjects (n = 22). Our network-centrality
analysis reveals a widespread decrease in connectivity in
most cortical and subcortical areas. In the cerebellum and
thalamus, however, we find localized increases. These rapid
and brain-encompassing connectivity changes linked to
acute serotonin transporter blockade suggest a key role
for the serotonin transporter in the modulation of the func-
tional macroscale connectome.
Results and Discussion
Serotonin is a key neuromodulator and plays an important role
in balancing mood, cognitive control, many endocrine and
autonomic processes, and sensorimotor output and percep-
tion [1]. Serotonergic projections innervate a multitude of
cortical and subcortical brain regions [5]. However, the extent
to which the brain’s intrinsic functional connectivity can be*Correspondence: sacher@cbs.mpg.dealtered by an acute serotonergic challenge is not known. The
serotonin transporter (5-HTT) is essential for maintaining
adequate brain serotonin homeostasis, and alteration of its
function has been linked to heightened susceptibility for
depression and anxiety [6–8]. It is also themain target of action
for selective serotonin reuptake inhibitors (SSRIs), the most
widely prescribed class of antidepressants worldwide [9].
Administration of an acute dose of an SSRI has been shown
to raise serotonin levels in frontal cortex, striatum, hippocam-
pus, and raphe nucleus [10–12]. This effect is regularly used to
investigate the consequences of acutely enhanced seroto-
nergic transmission in the human brain in vivo [13–15]. In vivo
neurochemical imaging of the human brain on an employable
timescale has been a methodological challenge. However,
investigating the alterations in global connectivity induced
by a pharmacological modulation using noninvasive rs-fMRI
offers a window to elucidating the link between neurochemical
systems and intrinsic brain organization. Resting-state func-
tional magnetic resonance imaging (rs-fMRI) focuses on the
assessment of spontaneous low-frequency fluctuations in
the absence of any task [16]. Connectivity measures between
these spontaneous fluctuations in brain activity have been
observed to reflect communication across large-scale net-
works in the human brain [17–19]. The capacity of serotonin
to impact functional connectivity in specific areas of the hu-
man brain has recently been demonstrated [2–4] but the full
potential of rs-fMRI to advance our understanding of how
serotonin and functional connectivity changes relate has not
yet been explored. Previous reports on SSRI-induced func-
tional connectivity changes by rs-fMRI were restricted to
single-seed [2, 3] or single-network [4] analysis. Our aims in
the current study were to investigate whether the impact of
SSRI-induced change in functional connectivity extends to
the entire human brain and to explore whether such a whole-
brain connectivity change is in fact a consistent decrease as
previous research indicates [2–4].
Given the widespread distribution of the serotonergic sys-
tem, we hypothesized that an acute serotonergic challenge
would have a large-scale impact on the intrinsic functional
connectivity of most cortical and subcortical areas and should
not be limited to specific networks. To this end, we measured
changes in connectivity using degree centrality [20] in antide-
pressant-naive and medication-free volunteers (n = 22; 11
females; age, 25; SD, 2) who engaged in a double-blind,
placebo-controlled, two-way cross-over design (for overview,
see Figure 1; for details on study design, image processing,
and analysis, see Supplemental Experimental Procedures
available online) and underwent three resting-state scanning
sessions: after a baseline rs-MRI scan, participants received
either a single oral dose of the study drug escitalopram
(20 mg) or placebo in a randomized design (separated
by a wash-out period of 8 weeks). MRI scanning was
scheduled during themaximum concentration of escitalopram
in blood, between 3 and 4 hr [21] after drug administration.
Plasma levels of escitalopram were 25 6 13; 16–57 (mean 6
SD; range) ng/ml.
We found a single dose of selective serotonin reuptake
inhibitor to spark a widespread connectivity decrease
throughout the brain (Figure 2): we report a global synchrony
Figure 1. Study Design
Twenty-two subjects underwent three resting-
state scanning sessions: after a baseline rs-MRI
scan, participants received either a single oral
dose of the study drug escitalopram (20 mg) (de-
picted by a red star) or placebo (depicted by a
green rectangle) in a randomized design. Serum
levels of escitalopram were determined after
3 hr followed by a second rs-fMRI scan. After a
wash-out period of 8 weeks, the protocol was
repeated with the alternate study drug (escitalo-
pram or placebo) to adhere to a double-blind in-
traindividual design. rs-fMRI scans are indicated
as blue circles.
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2315change revealing a widespread decrease in connectivity in
most cortical and subcortical areas (p < 0.01, cluster-cor-
rected) at the peak concentration of a single dose of 20 mg
escitalopram (Figure 2). In the placebo condition, we did not
find any significant clusters at this threshold. Our analysis
also revealed substantial regional differences in connectivity
change: we observed localized increases in connectivity
from cerebellar and thalamic regions in addition to a connec-
tivity decrease in most cortical and subcortical areas. Figure 3
displays the contrast in degree centrality of escitalopram
versus placebo: we report a general decrease in functional
connectivity throughout the brain, with the exception of local-
ized increases in cerebellar and thalamic regions (p < 0.01,
cluster-corrected). Figure S3 depicts the contrast at a range
of thresholds (r > 0.10, r > 0.15, r > 0.20). Table S1 provides a
comprehensive overview of all significant clusters in the esci-
talopram versus placebo condition.
To explore a potential influence of escitalopram on signal
properties, which could account for the connectivity findings,
we computed the power of the resting-state signal [17]. In the
analysis of the amplitude of low-frequency fluctuations (ALFF),
we did not find any significant changes when contrasting esci-
talopram to placebo condition. Hence, the signal change
depicted in Figure 3 appears to be more specific to the con-
nectivity between regions (for further details on connectivity
changes within and between networkmodules, see Figure S1),
providing support for the interpretation of our results as a
reflection of an alteration in functional synchronization rather
than a loss of power in the resting state signal.
To investigate whether the functional connectivity changes
we find reflect short-range or long-range connections, we
calculated the distance of each connection. Figure 4 shows
that the change in functional connectivity of the majority of
connections (reflected in red) occurs within the long-range dis-
tance of 6–12 cm. This analysis supports a conceptual frame-
work of serotonergically modulated functional connectivity in
long-range circuits. This finding draws further support from
electrophysiological data demonstrating serotonin to drive
long-range connections from both cerebellar cortex [22] and
contralateral cortico-cortical projections [23]. Complimentary
analyses of the functional connectivity change mapped on
major network modules [24] reveal the change in functional
connectivity to span across all major functional networks of
the brain (see Figures S1 and S2 and details in Supplemental
Data).We acknowledge that degree central-
ity is a measure that can be viewed as
difficult to relate to function in a specificcognitive domain or a particular aspect of emotional process-
ing. However, there is a consensus among experts [25, 26] that
although interpreting intrinsic functional connectivity faces
constraints both from static anatomical connectivity and
from poorly understood dynamic functional coupling changes
[25], this powerful technique provides unique insights into hu-
man brain organization. We therefore view our findings as an
essential first step for establishing the framework for future
behavioral- and task-based studies in clinical populations.
Some of our whole-brain results are consistent with previ-
ous seed-based studies indicating functional connectivity
decreases following SSRI administration in subcortical and
cortical areas [2–4]. However, our findings challenge the view
that SSRI-induced changes are limited to decreases in con-
nectivity, as we demonstrate substantial regional differences
in connectivity change following escitalopram intake: a series
of animal studies find total citalopram concentrations to be
twice as high in cortex compared to the citalopram levels in
mesencephalon-pons following chronic [27] and single-dose
[28] administration. These data are consistent with evidence
from human PET studies reporting regional differences in
glucose-metabolism changes following acute versus chronic
SSRI administration [29], differences in 5-HTT occupancy
rates after a single dose of an SSRI [30], as well as differences
in acute SSRI effects on endogenous serotonin concentration
levels [31] and the regional differences in functional connectiv-
ity between cortical andmore central brain regionswe observe
after a single, clinically relevant dose of escitalopram.
In the study by Nord et al. [31], a single dose of escitalopram
was found to decrease serotonin in cortical serotonergic pro-
jection areas while a trend for an increase in serotonin levels
was found in central serotonergic brain regions. This is of
particular interest as it had long been hypothesized that extra-
cellular serotonin rises after acute SSRI administration in the
entire brain. In light of recent findings supporting a decrease
in serotonin levels in cortical projections areas [31], it seems
likely that the effect of SSRIs on extracellular serotonin levels
differs among brain areas. This observation fits well with our
data suggesting that a single dose of escitalopram affects
functional connectivity differently in distinct brain areas.
Parameters like blood flow, lipophilicity, 5-HTT density, and
5-HTT internalization processes are likely to contribute to
those regional differences and we are just beginning to sys-
tematically study these regional differences in the context
of the time frame of drug administration. A systematic
Figure 2. Comparison of Average Degree Cen-
trality Baseline versus Placebo and Escitalopram
Sagittal slices of mean degree centrality of three
conditions: (A) baseline, (B) placebo, and (C) esci-
talopram (20mg), superimposed on a T1-anatom-
ical standard template. Orange colors indicate
higher centrality. Baseline and placebo condition
show more similar centrality patterns, whereas
degree centrality analysis reveals a global signal
change following the administration of the SSRI.
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2316categorization of these regional differences that have been
observed for acute, subacute, and chronic effects of SSRI
administration on brain metabolism, neurochemistry, and
intrinsic connectivity will be needed before the potential of
these neural correlates to guide psychopharmacological treat-
ment decisions can be evaluated.
While we observed a widespread decrease in connectivity in
most subcortical and cortical areas, localized increases were
observed in cerebellar and thalamic regions. The increase in
connectivity found in the thalamus and cerebellum may be of
particular relevance for the excitability of the many seroto-
nergic projection neurons that terminate in the thalamus [32].
Cerebellar input to the thalamus has been well established
[33–35] and cerebellar projections could be implicated in the
neuronal switch from burst into tonic mode. This switch has
been hypothesized to alert cortical networks [36] and demon-
strated to be central to performance in higher cognitive tasks
[37]. Cerebellar projections via the thalamus to cortical regions
are currently discussed to not purely serve movement but to
also play an important role for cognition and emotion regula-
tion [38]. Such behavioral changes have mostly been associ-
ated with lesions in areas of the posterior cerebellum [39]Figure 3. Signal Change in Degree Centrality Induced by a Single Dose of Esc
Sagittal slices show the contrast of degree centrality between placebo and escit
Orangecolors indicate increasedcentrality; blue colorsdecreased centrality follo
clusters (p < 0.01, corrected for multiple comparisons). Significant increases in d
degree centrality were found throughout the neocortex. Position of sagittal slice
all significant clusters in the escitalopram versus placebo condition. Figure S3 dthat correspond to the cerebellar regions we find the strongest
increase in connectivity induced by the SSRI.
While a role for serotonin has been well established in many
stages of neuroplasticity, such as modulation of neural cell
proliferation, migration, and differentiation as well as neurite
outgrowth, axonal guidance, synaptogenesis, and efficiency
of transsynaptic signaling [40], most of these effects are
believed to require a long duration to occur. It has been postu-
lated that the potential neuroplastic effects of antidepressants,
such as the SSRIs, are expected to take several weeks to un-
fold [41], a time frame that nicelymaps onto the period typically
required to see an effective clinical response to this class of
drugs [42]. However, several lines of evidence point toward
the acute potential of an increase in extracellular serotonin to
induce synaptoplastic effects, e.g., through the rapid activa-
tion of tropomyosin related kinase (Trk)-B-phospholipase-C
(PLC)-1-cAMP response element-binding (CREB) signaling
[43]. Most investigators interpret data indicating serotonin-
induced changes in Trk signaling and brain-derived neurotro-
phic factor (BDNF) secretion as an acute mechanism, whereas
serotonergic modulation of BDNF expression levels is consid-
ered a chronic process. Interestingly, there are also reportsitalopram Contrasted with Placebo
alopram condition superimposed on a T1-anatomical standardMNI template.
wingSSRI administration compared toplacebo.Dark lines indicate significant
egree centrality are located in the thalamus and the cerebellum; decreases in
s is shown in one axial slice. Table S1 provides a comprehensive overview of
epicts the contrast at a range of thresholds (r > 0.10, r > 0.15, r > 0.20).
Figure 4. Change of Functional Connectivity between the Placebo and SSRI
Condition and Euclidean Length of Connection
The x axis indicates the Euclidean distance (mm) between the two end-
points of the respective connection. The y axis displays the mean functional
connectivity difference (placebo-SSRI). The color indicates the number of
connections, with hot colors reflecting a high number of connections with
specific distance and change and blue colors indicating fewer connections.
For further details on connectivity changes within and between network
modules, see Figures S1 and S2.
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2317that support an acute effect of serotonin on BDNF expression
levels [44] and many questions remain unanswered regarding
the timeline from initiation of a neuroplastic process to how
long this process is sustained. Exploring functional connectiv-
ity changes that potentially reflect an early marker for neuro-
plastic change in vivo in the light of a serotonergic challenge
thus seems a valuable strategy to conceptualize a model for
the time frame of serotonergic action in the human brain.
Main Findings and Implications
We demonstrate an acute and widespread decrease in func-
tional connectivity across the whole brain following the oral
intake of a single dose of escitalopram in healthy subjects,
as well as the change in connectivity not to be limited to a
decrease but to be paralleled with localized increases in
cerebellar and thalamic regions. These findings provide evi-
dence for the particular relevance of serotonin for the
modulation of intrinsic brain activity and also demonstrate its
unique influence on the cerebello-thalamic tract. The ob-
served link between rapid serotonin transporter blockade
and such fundamental functional connectivity change across
the whole brain suggests a very early initiation time for
serotonin-inducedmodulation of functional connectivity archi-
tecture. While further research is needed to establish whether
these serotonin-induced connectivity changes hold promise
to translate into meaningful predictors for antidepressant
response, our findings represent a first step toward identifying
an intrinsic functional connectome print for individual respon-
sivity of the human brain to serotonergic modulation.
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